CTLA4 methylation predicts response to anti–PD-1 and anti–CTLA-4 immunotherapy in melanoma patients

Recent years have witnessed the groundbreaking success of immune checkpoint blockage (ICB) in metastasized malignant melanoma. However, biomarkers predicting the response to ICB are still urgently needed. In the present study, we investigated CTLA4 promoter methylation (mCTLA4) in 470 malignant mela...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:JCI Insight
Main Authors: Goltz, Diane, Gevensleben, Heidrun, Vogt, Timo J., Dietrich, Joern, Golletz, Carsten, Bootz, Friedrich, Kristiansen, Glen, Landsberg, Jennifer, Dietrich, Dimo
Formato: Artigo
Idioma:Inglês
Publicado: American Society for Clinical Investigation 2018
Assuntos:
Research Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6124533/
https://ncbi.nlm.nih.gov/pubmed/29997292
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.96793
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares